Abstract:Abstract Cancer immunotherapy has achieved notable clinical success, yet its broader application is impeded primarily by immune evasion mechanisms, predominantly stemming from factors such as tumor antigen loss, intrinsic low antigen presentation, and the inherent impermeability of current macromolecules, including cells, antibodies, and proteins. Consequently, there exists a pressing demand for more permeable agents that target intracellular components as viable alternatives. Among the various molecular players involved in immune evasion, PTPN1 and PTPN2, two protein tyrosine phosphatases (PTPs), play a non-redundant role in regulating tumor antigen presentation. They achieve this by modulating the JAK/STAT signaling pathway within tumor cells, with their deletion having been demonstrated to enhance MHC-I presentation across various cell types. Furthermore, PTPN1 and PTPN2 also negatively regulate T cell receptor (TCR) signaling in T cells, as supported by genetic studies. Consequently, these two proteins present as promising targets for the development of innovative cancer immunotherapies due to their dual impact on both tumor cells and T cells. Addressing the intrinsic impermeability challenges associated with macromolecules, we embarked on the development of small molecule agents that specifically target PTPN1 and PTPN2, culminating in the successful creation of a low-nanomolar proteolysis targeting chimera (PROTAC), designated as X1. PROTAC X1 exhibits sustained low-nanomolar binding affinity and exceptional selectivity toward PTPN1 and PTPN2 in in vitro settings. Furthermore, it has demonstrated a nano-molar half-maximal degradation concentration (DC50) in Jurkat T cells and numerous cancer cell lines, while concurrently exhibiting efficacy in eliciting TCR signaling and enhancing MHC-I presentation. Additionally, X1-treated CAR-T cells exhibited augmented cytotoxicity through increased IFN-γ secretion, thereby reinforcing its efficacy in T cell activation. To ascertain the anti-tumor efficacy of X1, we administered X1 to C57BL/6 mice bearing MC38 tumors, resulting in a significant retardation of tumor progression. Subsequent investigations revealed that X1 treatment induced an inflammatory response in the tumor microenvironment, characterized by enhanced T cell infiltration and the activation of CD8+ T cells. Notably, no discernible adverse effects, such as autoimmune symptoms, were observed during treatment. Collectively, these findings indicate that X1 represents a potent and safe agent for cancer immunotherapy. This study not only elucidates the mechanism of action of PTPN1B/TC-PTP pharmacological degradation as a viable approach for cancer treatment but also solidifies the potential of PTPN1B/TC-PTP degradation as a novel avenue for cancer immunotherapy. Citation Format: Zihan Qu, Yunpeng Bai, Jiajun Dong, Zheng Zhang, Bo Huang, Yiming Miao, Andy W. Tao, Philip S. Low, Zhong-Yin Zhang. Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4505.

Abstract 4514: Discovery of potent and orally bioavailable degraders of HPK1 based on a novel HPK1 binder

Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy

Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy

An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti-Solid Tumor Immunity.

Abstract 4505: Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy

Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion

Abstract 3517: Pharmacologic inhibition of HPK1 kinase activity enhances immune cell activation and T cell mediated anti-tumor activity

Abstract 2097: ABT co-dose accelerated target validation with a fit-for-purpose HPK1 inhibitor tool

Abstract LB179: Identification of the highly potent and orally available ER-targeting PROTAC degrader HP568 for the treatment of breast cancer

Abstract 6510: BPI-511966,a potent and selective HPK1 inhibitor with robust single-agent efficacy for cancer immunotherapy

Abstract 4515: Orally bioavailable PROTAC based MDM2 degrader

Abstract 3450: Discovery and preclinical study of novel BTK degrader HZ-Q1070

Abstract 5322: Discovery of CRD1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity

Abstract 4512: Discovery of highly potent, selective, and orally bioavailable IKZF2 degrader and its anti-tumor activity in syngeneic mouse models

Abstract 3967: ISM9182A, a novel HPK1 inhibitor, exhibits immune modulatory activity and robust monotherapy anti-tumor effects in preclinical studies

Abstract LB324: BB3008, a potent and selective small molecular HPK1 inhibitor effective in multiple syngeneic tumor models

Abstract 4504: Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p300 PROTAC degraders for the treatment of castration-resistant prostate cancer

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Discovery of Potent and selective HPK1 Inhibitors Based on the 2,4-disubstituted Pyrimidine Scaffold with Immune Modulatory properties for Ameliorating T cell exhaustion

Abstract 2122: CRD1600 is a potent HPK-I inhibitor with robust immune modulatory properties

Abstract LB178: HP518, an oral AR-targeting PROTAC for the treatment of AR positive triple negative breast cancer with a novel mechanism of action